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Objectives This study sought to investigate clinical utility of on-site platelet function test and C-reactive protein (CRP) in pa-
tients undergoing percutaneous coronary intervention (PCI).
Background Data on long-term prognostic value of high on-treatment platelet reactivity (HTPR) on clopidogrel after PCI are
limited. As a distinct biological pathway, CRP has been suggested to be associated with post-PCI atherothrom-
botic events.
Methods We evaluated 2,849 patients who received drug-eluting stents (DES) and had post-PCI VerifyNow P2Y12 assays
(Accumetrics, San Diego, California) performed. Among them, baseline CRP measurement was available in
2,546 patients. The primary endpoint was a composite of all-cause death, nonfatal myocardial infarction, stent
thrombosis, and stroke.
Results During follow-up (median, 2.2 years), the occurrence of the primary endpoint did not significantly differ among
patients with and without HTPR (2.8% vs. 2.4% at 2 years; hazard ratio [HR]: 1.33, 95% confidence interval [CI]:
0.88 to 2.01; p  0.18). By contrast, patients with elevated CRP levels were at significantly higher risk for the
primary endpoint, as compared with those with nonelevated CRP levels (5.6% vs. 1.7% at 2 years; HR: 2.81,
95% CI:, 1.83 to 4.31; p  0.001). The VerifyNow test had no incremental usefulness to classify long-term risk.
However, the incorporation of CRP into a model with conventional clinical and procedural risk factors signifi-
cantly improved the C-statistic for the prediction of the primary endpoint (0.729 to 0.759; p  0.03).
Conclusions We failed to identify that HTPR measured by VerifyNow P2Y12 assay was significantly associated with long-term
atherothrombotic risks in patients receiving DES. However, elevated CRP levels were significantly associated
with worse outcomes and had incremental predictive values over conventional risk factors. (J Am Coll Cardiol
2011;58:2630–9) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.057The clinical importance of clopidogrel has been intensified in
patients undergoing percutaneous coronary intervention (PCI)
with drug-eluting stents (DES), which have been associated
with the ongoing propensity for late stent thrombosis, neces-
sitating the prolonged use of dual antiplatelet therapy (1).
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been observed, and high on-treatment platelet reactivity
(HTPR) is associated with adverse ischemic events after
PCI (2). Multiple studies suggested a relationship between
HTPR, measured by point-of-care assays, and post-PCI
ischemic events (3–6). However, these studies were ham-
pered by the small number of events, few patients,
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or limited duration of follow-up. It is unknown whether
HTPR associated with the risks for periprocedural or
mid-term events are the same as those associated with
long-term risks.
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marker C-reactive protein (CRP) has been postulated to be a
hemostatic risk factor predicting atherothrombosis, and our
previous observation suggested that a high level of CRP was
associated with stent thrombosis or major cardiovascular
events in patients treated with DES (7,8).
Coupled with suggested relationships of HTPR and CRP
with serious clinical events, enhanced risk assessment with
addition of these laboratory assays on conventional clinical
and procedural risk factors would be of great clinical value if
it could more accurately identify “high-risk” patients.
Therefore, as a primary study objective, we tested the
hypothesis that HTPR measured by the VerifyNow P2Y12
assay (Accumetrics, San Diego, California) is associated
with long-term atherothrombotic events in patients receiv-
ing DES. Secondarily, on an a priori basis, we compared the
incremental usefulness of onsite platelet function assay and
CRP from different biological pathways to predict clinical
outcome in such patients.
Methods
Study population. Patients were eligible to be enrolled if
they had undergone PCI with at least 1 DES for stable
angina or ischemia, or non–ST-segment elevation acute
coronary syndromes. Study patients were consecutively en-
rolled at the Asan Medical Center (Seoul, Korea) between
March 2006 and December 2009. All patients undergoing
PCI were prescribed aspirin (loading dose, 200 mg) and
received optimal clopidogrel treatment (defined as a main-
tenance of 75 mg/day therapy for 5 days or a loading dose
of 300 or 600 mg 12 h before PCI). After the procedure,
patients were prescribed aspirin (100 to 200 mg once daily)
indefinitely and clopidogrel (75 mg once daily) for at least
12 months, regardless of DES type. Treatment beyond this
duration was at the discretion of the physician.
Patients with ST-segment elevation acute myocardial
infarction (MI), those with periprocedural use of glyco-
protein IIb/IIIa inhibitors, and those with a known platelet
function disorder or thrombocytopenia (platelet count of
80  103/l) were excluded. Patients were also excluded
if they presented with cardiogenic shock, had concomitant
inflammatory conditions (such as active infection, inflam-
matory arthritis, or connective tissue disease) or malignan-
cies, or had a contraindication to aspirin or clopidogrel.
This study was approved by the institutional review board
of Asan Medical Center, and all patients provided written
informed consent.
Laboratory measurements of platelet reactivity and CRP.
Platelet function was assessed with the VerifyNow P2Y12
test 24 to 48 h post-PCI, the time at which the study
patients would be expected to be near or at their steady-state
level of platelet inhibition immediately before discharge.
This test has been previously described in detail (9). The
instrument measures platelet-induced aggregation as an
increase in light transmittance and uses a proprietary algo-rithm to report values in P2Y12
reaction units (PRU). The device
also provides an estimated inhi-
bition without a pre-clopidogrel
sample by reporting the ratio of
the results of the ADP-PGE1
and iso-TRAP channels (Veri-
fyNow % inhibition).
Considering the biological
plausibility and the reported as-
sociations with cardiovascular
events, we also measured baseline
CRP levels in study patients.
Fasting blood samples were ob-
tained in the morning before the
procedure. CRP was assayed
using a latex-enhanced high-
sensitivity CRP immunoassay (COBAS INTEGRA,
Roche Diagnostics, Mannheim, Germany) (8). All labora-
tory testing (VerifyNow P2Y12 assay and CRP values) was
performed by personnel blinded to patient information and
study objectives.
Endpoints, definitions, and follow-up. The primary end-
point was the first occurrence of major cardiovascular events
defined as a composite of all-cause death, nonfatal MI, stent
thrombosis, and stroke. The principal secondary endpoints
were death from any cause; MI, stent thrombosis; stroke
(from any cause); target vessel revascularization; a composite
of cardiovascular death, nonfatal MI, stent thrombosis, or
stroke; and bleeding, according to the Thrombolysis In
Myocardial Infarction (TIMI) criteria (10).
All deaths were considered to be from cardiovascular
causes unless an unequivocal noncardiovascular cause could
be established. The diagnosis of acute MI was based on the
universal definition of MI (11). Periprocedural or post-
procedural elevations of cardiac enzymes were disregarded if
ischemic signs or symptoms were absent. Stent thrombosis
was assessed by the Academic Research Consortium criteria
(12), with the pre-specified component of primary compos-
ite outcome being definite or probable. Stroke, as detected
by the occurrence of a new neurological deficit, was con-
firmed by a neurologist and on imaging. Target vessel
revascularization was defined as any percutaneous or surgical
revascularization of the target vessel. Major and all types of
(major, minor, or minimal) bleedings were assessed in
accordance with TIMI criteria. All study endpoints were
confirmed on the basis of source documentation from
medical records and were adjudicated by an independent
group of clinicians blinded to the VerifyNow P2Y12 assay
and CRP values.
In this study, HTPR was defined by a PRU value 235
and/or a % inhibition 15%. This cutoff was chosen
because it was similar to the cutoff (PRU and % inhibition)
suggested by a prior observation of a similar ethnic popu-
Abbreviations
and Acronyms
CI  confidence interval
CRP  C-reactive protein
DES  drug-eluting stent
HR  hazard ratio
HTPR  high on-treatment
platelet reactivity
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PRU  P2Y12 reaction
unit(s)
TIMI  Thrombolysis In
Myocardial Infarctionlation that used receiver-operator characteristic curve anal-
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assay for prediction HTPR on standard light transmittance
aggregometry (13). The cutoff is also similar with other
studies (14,15). Based on the cutoff point suggested in the
literature and in our previous report (8,16), CRP levels 3
mg/l were considered elevated. These cutoff points of the
P2Y12 assay and CRP values were pre-specified in the study
protocol. In our practice, alteration of antiplatelet therapy
was not done according to the results of the VerifyNow
P2Y12 assay or CRP measurements.
Clinical, procedural, and outcome data were prospectively
collected by independent research personnel unaware of the
study aims and entered into a central database, as previously
described (8). Clinical follow-up after PCI was performed
via office visit or telephone contact at 1, 6, and 12 months
and then every 6 months thereafter. At these visits, data
pertaining to patients’ clinical status, all interventions, outcome
events, and adverse events were recorded. Adherence to anti-
platelet medication was routinely assessed at each time of
follow-up contact and also verified by pharmacy refill data. For
validation of complete follow-up data, information about vital
status was obtained from the National Population Registry of
the Korea National Statistical Office with the use of a unique
personal identification number.
Statistical methods. Continuous variables are presented as
mean  SD and were compared with the t test or Mann-
Whitney U test. Categorical variables are reported as fre-
quencies (%) and were compared with the chi-square
statistic or Fisher exact test, as appropriate.
Figure 1 Study Profile
High on-clopidogrel platelet reactivity was defined by a P2Y12 reaction unit value 
Elevated C-reactive protein (CRP) level was defined as value 3 mg/l. MI  myocA total sample of 3,000 observations was computed to
achieve 90% power at a 2-sided 0.05 significance level to
detect a hazard ratio (HR) 2.0 with a Cox regression of
the log HR on a binary covariate (high vs. normal on-
treatment platelet reactivity) with a 25% or greater preva-
lence. The sample size was adjusted for an anticipated rate
of the primary endpoint of 4.0% at a median follow-up of 2
years (17).
We used a Cox proportional hazards model to compare
clinical endpoints between patients with HTPR and those
without HTPR. In addition, the relationship between
different degrees of platelet reactivity (PRU or % P2Y12
inhibition by quintiles or continuous model) and outcomes
were evaluated. Survival analysis for patients with and
without HTPR was performed using the Kaplan-Meier
method, and the differences between groups were assessed
by the log-rank test.
After evaluating the relation to CRP to clinical outcomes
with the use of Cox proportional hazards regression, we
compared the incremental value of incorporating HTPR or
elevated CRP levels into the context of conventional clinical
and procedural characteristics, for prediction of primary end-
point. Estimates of the C-statistic for the Cox regression
models were calculated according to the method of Pencina et
al. (18). Differences in C-statistics (with 95% confidence
interval [CI]) after the addition of the laboratory markers to a
model with conventional clinical and procedural risk factors
were obtained through the bootstrap percentile method (200
replicates) (19). All reported p values are 2-sided, and p values
nd/or a % inhibition 15%, as measured by the VerifyNow P2Y12 assay.
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software, version 9.1 (SAS Institute, Cary, North Carolina)
was used for statistical analysis.
Results
Patient characteristics. During enrollment period, 3,370
patients underwent an index PCI and had VerifyNow P2Y12
assays performed 24 to 48 h after the procedure. Among them,
a total of 2,849 patients met the study inclusion criteria and
met none of the criteria for exclusion (Fig. 1).
Baseline characteristics of the entire population and of
the patients according to the magnitude of platelet reactivity
are shown in Table 1. HTPR was observed in 58.3% of the
study population. Covariates of HTPR included older age,
female sex, higher body mass index, and hypertension.
Types of DES used were sirolimus-eluting stents (41.5% of the
population), paclitaxel-eluting stents (12.5%), zotarolimus-
eluting stents (19.9%), everolimus-eluting stents (15.5%), Res-
lute zotarolimus-eluting stents (8.0%, Medtronic, Minne-
polis, Minnesota), and other DES (2.5%), and did not
ignificantly differ among patients with or without HTPR.
tatus of antiplatelet therapy and cardiac-related medica-
ions are summarized in Table 2. All patients received
Baseline Characteristics of the Patients, Accordof On-Treatment Platelet ReactivityTable 1 B seline Charact ris ics of the Patof On-Treatment Platelet Reactivity
Variable
Overall Pop
(N  2,8
Clinical characteristics
Age, yrs 61.7 9
Male 2,027 (7
Body mass index, kg/m2 25.0 2
Diabetes 811 (2
Hypertension 1,677 (5
Current smoking 712 (2
Hypercholesterolemia 1,739 (6
Previous myocardial infarction 167 (5
Previous PCI 514 (1
Previous bypass surgery 80 (2
Previous stroke 141 (4
Renal insufficiency 50 (1
Clinical indication
Stable angina 1,586 (5
Acute coronary syndrome 1,264 (4
Ejection fraction 59.3 6
Procedural characteristics
Multivessel disease 1,469 (5
Left anterior descending artery 2,095 (7
Left main disease 307 (1
ACC/AHA lesion B2 or C type lesions 2,295 (8
Bifurcation lesion 1,009 (3
No. of stents implanted 2.0 1
Total stent length, mm 50.3 3
Minimal stent diameter, mm 3.1 0Values are mean  SD or n (%).
ACC/AHA  American College of Cardiology/American Heart Association;optimal clopidogrel pre-treatment before the VerifyNow
P2Y12 assay. The status of dual antiplatelet therapy at
different time intervals did not differ between patients with
and without HTPR.
Association of VerifyNow P2Y12 assay with clinical
outcomes. The median follow-up was 2.2 years (interquartile
range: 1.3 to 3.4 years). Clinical follow-up completeness is
shown in Table 2. During follow-up, the primary endpoint
occurred in 96 patients (2-year cumulative rate, 2.6%); a total
of 72 patients died, 10 patients had nonfatal acute MI, 6 had
definite or probable stent thrombosis, and 26 had a stroke.
Target vessel revascularization was performed in 140 patients,
and major bleeding occurred in 27 patients.
The Kaplan-Meier estimate of the event rate for the primary
endpoint at 2 years was 2.8% in patients with HTPR and 2.4%
in patients without HTPR (HR: 1.33; 95% CI: 0.88 to 2.01;
p 0.18) (Fig. 2, Table 3). Overall results were the same if just
a PRU value235 was used for the definition of HTPR (with
this criteria, 56.0% had HTPR; HR: 1.37; 95% CI: 0.91 to
2.07; p  0.13). Stratification by quintiles based on platelet
reactivity (PRU value or % P2Y12 inhibition) also demon-
trated no significant difference in primary outcomes among
uintiles (Online Fig. 1). In addition, PRU value (HR: 1.001,
o the Magnitude, According to the Magnitude
On-Treatment Platelet
Reactivity
High
(n  1,660)
Normal
(n  1,189) p Value
62.6 9.5 60.4 9.9 0.001
1,121 (67.5) 906 (76.2) 0.001
25.1 2.9 24.9 2.9 0.02
482 (29.0) 329 (27.7) 0.43
1,013 (61.0) 664 (55.8) 0.006
400 (24.1) 312 (26.2) 0.19
1,028 (61.9) 711 (59.8) 0.25
90 (5.4) 77 (6.5) 0.24
281 (16.9) 233 (19.6) 0.07
50 (3.0) 30 (2.5) 0.44
90 (5.4) 51 (4.3) 0.17
32 (1.9) 18 (1.5) 0.41
0.85
921 (55.5) 664 (55.8)
739 (44.5) 525 (44.2)
59.2 6.7 59.5 7.0 0.24
845 (50.9) 624 (52.5) 0.41
1,204 (72.5) 891 (74.9) 0.15
159 (9.6) 148 (12.4) 0.02
1,332 (80.2) 963 (81.0) 0.62
601 (36.2) 408 (34.3) 0.30
2.0 1.1 2.1 1.2 0.32
50.0 31.4 50.8 31.7 0.52
3.1 0.4 3.1 0.4 0.14ing tie ts
ulation
49)
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1.006, 95% CI: 0.997 to 1.014, p  0.18) as a continuous
variable was not associated with increasing risk for the primary
endpoint. There was also no significant difference in the risk of
individual and composite secondary endpoints among patients
with or without HTPR.
Association of CRP levels with clinical outcomes. Base-
line CRP was concomitantly measured in 2,546 patients
(Fig. 1) and elevated CRP (3.0 mg/l) was observed in
24.7% of patients. Characteristics of the entire population
and of the patients according to elevated versus non-
elevated CRP levels are shown in Online Table 1.
During follow-up, there were progressive and signifi-
cantly higher increases in primary endpoint in patients with
elevated CRP levels than in those with non-elevated CRP
levels (Fig. 3, Table 4). These results were also consistent
with a broad range of clinical presentations (HR: 3.08, 95%
CI: 1.73 to 5.47, p  0.001 for stable angina vs. HR: 2.88,
95% CI: 1.50 to 5.55, p  0.002 for acute coronary
syndrome; p for interaction  0.64). The association re-
Status of Dual Antiplatelet Therapy and Cardiacand Clinical Follow-Up CompletenessTable 2 Status of Dual An iplatelet Therapyand Clinical Follow-Up Completenes
Characteristic
Clopidogrel loading at pre-procedure
75 mg/day for 5 days
300 mg 12 h before PCI
600 mg 12 h before PCI
Clopidogrel maintenance
At discharge 1,
6 months after procedure 1,
12 months after procedure 1,
18 months after procedure
24 months after procedure
Aspirin maintenance
At discharge 1,
6 months after procedure 1,
12 months after procedure 1,
18 months after procedure
24 months after procedure
Cardiac-related medications at discharge
ACE inhibitor
Beta-blockers
Calcium-channel blocker
Statin
Warfarin
Proton pump inhibitor
Clinical follow-up completeness after discharge
1 month after procedure 1,
6 months after procedure 1,
12 months after procedure 1,
18 months after procedure 1,
24 months after procedure
Values are n (%) or n/total n (%).
ACE  angiotensin-converting enzyme; PCI  percutaneous coronaained significant even after adjustment for other signifi- vant covariates or multiple potential confounders. The HRs
or each component of mortality, MI, stent thrombosis, or
troke or secondary composite outcome range from 2 to 3,
onsistently (but not always statistically significantly) higher
isk for patients with elevated CRP levels. However, there
as no association between CRP levels and the risk of
evascularization or bleeding.
ncremental usefulness of VerifyNow P2Y12 assay or
RP over conventional risk factors for prediction of
linical outcomes. Table 5 summarizes the improvements in
odel discrimination when adding HTPR or elevated CRP
evels into a model with the conventional clinical and proce-
ural risk factors for the prediction of the primary endpoint.
he addition of HTPR did not significantly improve the
-statistic for predicting outcomes. However, when elevated
RP levels were incorporated into the model with conven-
ional risk factors, the C-statistic increased significantly.
elationship and outcomes according to VerifyNow
2Y12 assay and CRP. There was no significant correla-
ion between the magnitude of platelet reactivity and CRP
ted MedicationsCardiac-Related Medications
n-Treatment Platelet Reactivity
p Value
igh
1,660)
Normal
(n  1,189)
0.28
507 (30.5) 396 (33.3)
,107 (66.7) 759 (63.8)
46 (2.8) 34 (2.9)
,660 (99.9) 1,188/1,189 (99.9) 0.99
,644 (97.6) 1,146/1,182 (97.0) 0.27
,578 (93.3) 1,041/1,135 (91.7) 0.12
,018 (81.9) 638/794 (80.3) 0.40
752 (71.7) 426/609 (70.0) 0.49
,660 (99.8) 1,186/1,189 (99.7) 0.70
,644 (98.5) 1,169/1,182 (98.9) 0.41
,578 (97.7) 1,101/1,135 (97.0) 0.25
,018 (95.6) 761/794 (95.8) 0.78
752 (93.5) 577/609 (94.7) 0.33
472 (28.4) 295 (24.8) 0.03
,149 (69.2) 806 (67.8) 0.42
,458 (87.8) 1,048 (88.1) 0.80
,325 (79.8) 936 (78.7) 0.48
12 (0.7) 6 (0.5) 0.47
47 (2.8) 26 (2.2) 0.28
,660 (99.9) 1,185/1,189 (99.7) 0.24
,650 (99.6) 1,182/1,184 (99.8) 0.48
,620 (98.9) 1,154/1,162 (99.3) 0.25
,080 (98.1) 831/845 (98.3) 0.75
826 (97.0) 662/682 (97.1) 0.92
vention.-Relaand
s
O
H
(n 
1
658/1
605/1
472/1
834/1
539/
657/1
620/1
542/1
973/1
703/
1
1
1
658/1
644/1
602/1
060/1
801/alues (Online Fig. 2). Kaplan-Meier curves of the cumulative
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December 13/20, 2011:2630–9 Platelet Function Test and CRP After PCIprobability of the primary endpoint according to the combined
status of platelet reactivity and CRP are illustrated in Figure 4. In
patients with elevated CRP levels, there was a continuous sepa-
ration of the events curves according to high versus normal platelet
Figure 2 Kaplan-Meier Curves of the Cumulative Probability of
According to High Versus Normal On-Treatment Platel
The primary endpoint was defined as a composite of all-cause death, nonfatal myo
was defined by a P2Y12 reaction unit value 235 and/or a % inhibition 15%, as
log-rank test.
Clinical Outcomes According to On-Treatment Platelet ReactivityTable 3 Clinical Outcomes According to On-Treatment Platelet
On-Tr
Total No. of Even
Outcome
High
(n  1,660)
N
(n 
Primary endpoint
Death, MI, stent thrombosis, or stroke 58
Secondary endpoints
Death 40
MI 6
Stent thrombosis
Definite 3
Definite or probable 4
Definite, probable, or possible 13
Stroke 17
Target vessel revascularization 78
Cardiovascular death, MI, stent thrombosis, or stroke 41
Bleeding, according to TIMI criteria‡
Major 17
All type 62
Cumulative event rates are derived from Kaplan-Meier estimates. *For each endpoint, first events
with patients with normal on-treatment platelet reactivity. ‡Bleeding according to TIMI criteria refers to a
CI  confidence interval; MI  myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.reactivity; however, these findings were not observed in patients
with non-elevated CRP levels (p 0.02 for interaction). Conse-
quently, patients with both HTPR and elevated CRP levels were
the highest-risk group for future atherothrombotic events.
rimary Endpoint
activity
l infarction, stent thrombosis, and stroke. High on-clopidogrel platelet reactivity
ured by the VerifyNow P2Y12 assay. p values were calculated with the use of the
tivity
nt Platelet Reactivity
Cumulative Event Rate
at 2 Years
9)
High
(n  1,660)
Normal
(n  1,189) Hazard Ratio† (95% CI) p Value
2.8 2.4 1.33 (0.88–2.01) 0.18
2.0 2.0 1.10 (0.69–1.75) 0.71
0.3 0.3 1.34 (0.37–4.83) 0.66
0.2 0.1 2.19 (0.23–21.05) 0.50
0.2 0.2 1.45 (0.27–7.92) 0.67
0.8 0.8 0.72 (0.34–1.51) 0.38
0.9 0.7 1.54 (0.68–3.47) 0.30
4.3 5.1 0.94 (0.67–1.31) 0.71
2.2 1.3 1.46 (0.88–2.43) 0.15
0.9 0.6 1.29 (0.59–2.83) 0.52
3.3 2.6 1.31 (0.87–1.98) 0.20
e counted. †Hazard ratios are for patients with high on-treatment platelet reactivity, as comparedthe P
et Re
cardia
measReac
eatme
ts*
ormal
1,18
38
32
4
1
2
15
9
62
24
10
36
only ar
djudicated events in accordance with previously used definitions (10).
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In our large cohort of patients with DES implantation, HTPR, as
measured by the VerifyNow P2Y12 assay, failed to predict
long-term risk of major cardiovascular events. By contrast, our
data suggested that elevated CRP levels were significantly associ-
Figure 3 Kaplan-Meier Curves of the Cumulative Probability of
According to Elevated Versus Nonelevated Levels of C
The primary endpoint was defined as a composite of all-cause death, nonfatal myo
Elevated C-reactive protein (CRP) level was defined as a value 3 mg/l. p values
Clinical Outcomes According to CRP LevelTable 4 Clinical Outcomes According to CRP Level
Total No. of Even
Outcome
Elevated
(n  630)
None
(n 
Primary endpoint
Death, MI, stent thrombosis, or stroke 39
Secondary endpoints
Death 31
MI 4
Stent thrombosis
Definite 2
Definite or probable 3
Definite, probable, or possible 13
Stroke 9
Target vessel revascularization 25 1
Cardiovascular death, MI, stent thrombosis, or stroke 27
Bleeding, according to TIMI criteria‡
Major 6
All 25
Cumulative event rates are derived from Kaplan-Meier estimates. *For each endpoint, first events o
with patients with non-elevated C-reactive protein level. ‡Bleeding according to TIMI criteria refer to adju
Abbreviations as in Table 4.ated with atherothrombotic events and also had incremental
predictive values beyond on classical risk factors.
In contrast with our findings, several studies suggested a
strong association between VerifyNow P2Y12 assays and
adverse events in patients with coronary stenting (3,6,14).
rimary Endpoint
l infarction, stent thrombosis, and stroke.
alculated with the use of the log-rank test.
RP Level
Cumulative Event Rate
at 2 Years
d
)
Elevated
(n  630)
Nonelevated
(n  1,916) Hazard Ratio† (95% CI) p Value
5.6 1.7 2.81 (1.83–4.31) 0.001
4.6 1.3 2.94 (1.81–4.79) 0.001
0.8 0.2 2.17 (0.61–7.71) 0.23
0.3 0.1 3.06 (0.43–21.74) 0.26
0.5 0.2 3.06 (0.62–15.14) 0.17
1.9 0.5 3.18 (1.47–6.86) 0.003
1.2 0.4 2.88 (1.17–7.10) 0.02
3.7 5.0 0.75 (0.48–1.16) 0.20
4.2 0.9 3.01 (1.78–5.08) 0.001
0.8 0.6 1.16 (0.46–2.97) 0.75
3.0 2.7 1.29 (0.81–2.06) 0.28
counted. †Hazard ratios are for patients with elevated C-reactive protein (CRP) level, as comparedthe P
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December 13/20, 2011:2630–9 Platelet Function Test and CRP After PCIHowever, given the small number of events, limited patient
populations, and the frequent use of glycoprotein IIb/IIIa
inhibitors highly interfering with the P2Y12 assay, some
studies should be interpreted with caution, and the robust-
ness of conclusions is limited (3,6). A recent large observa-
tional study suggested that the VerifyNow test was signifi-
cantly associated with atherothrombotic events (14). In this
study, however, HTPR cluster with traditional clinical risk
factors (i.e., old age, high body mass index, diabetes, low
ejection fraction) for cardiovascular events. Therefore, in-
dependent association of HTPR with clinical outcomes
after adjustment for these concomitant risk factors should be
evaluated to clarify whether “in vitro” platelet reactivity has
direct causality for clinical events or whether it functions as
just a marker.
C-Statistic for Cox Regression Models for Prediction of Primary EndTable 5 C-Statistic for Cox Regression Models for Prediction o
Model
Risk Factors and Laboratory Assay
Conventional clinical and procedural risk factors*
Conventional clinical and procedural risk factors plus HTPR†
Conventional clinical and procedural risk factors plus elevated CRP levels‡
Conventional clinical and procedural risk factors plus HTPR and elevated CRP levels
*Conventional clinical risk factors were age, sex, body mass index, diabetes, hypertension, hyperc
acute coronary syndrome; conventional procedural risk factors were multivessel disease, America
number of stent, total stent length, and minimal stent diameter. †High on-clopidogrel platelet rea
the VerifyNow P2Y12 assay. ‡Elevated CRP level was defined as a value 3 mg/l.
CI  confidence interval; CRP  C-reactive protein; HTPR  high on-treatment platelet reactivi
Figure 4 Kaplan-Meier Curves of the Cumulative Probability of
According to the Status of Both On-Treatment Platele
Groups were represented according to decreasing incidence of the primary endpoi
elevated C-reactive protein (CRP) levels; group 2 indicates patients (n  238) with
patients (n  822) with normal on-treatment platelet reactivity and non-elevated C
reactivity and non-elevated CRP levels. High on-clopidogrel platelet reactivity was d
by the VerifyNow P2Y12 assay. Elevated CRP level was defined as a value 3 mgThe GRAVITAS (Gauging Responsiveness with A
VerifyNow assay–Impact on Thrombosis And Safety) trial
is the first large-scale clinical trial to test tailored antiplatelet
therapy based on the VerifyNow P2Y12 assay in patients
who received DES (15). This trial does not support high-
dose clopidogrel in patients with HTPR. In addition,
similar to our findings, there was no significant association
of HTPR with the clinical endpoint in patients on standard
clopidogrel therapy; moreover, this association could be
weaker if adjustment for a higher prevalence of concomitant
risk factors in the high-reactivity group were to be done.
However, because of the relatively small number of events
and a clinically low-risk population in both cases—the
GRAVITAS trial and the current study—more large clin-
ical studies with longer-term follow-up are mandatory to
tary Endpoint
C-Statistic Estimated Difference (95% CI) p Value
0.729 Referent Referent
0.733 0.003 (0.007 to 0.013) 0.54
0.759 0.031 (0.002 to 0.058) 0.03
0.762 0.032 (0.003 to 0.062) 0.03
rolemia, previous myocardial infarction, previous stroke, renal insufficiency, ejection fraction, and
e of Cardiology/American Heart Association lesion B2 or C type lesions, bifurcation lesions, total
as defined by a P2Y12 reaction units (value 235 and/or a % inhibition 15%, as measured by
rimary Endpoint,
ctivity and CRP
up 1 indicates patients (n  392) with high on-treatment platelet reactivity and
al on-treatment platelet reactivity and elevated CRP levels; group 3 indicates
els; and group 4 indicates patients (n  1,094) with high on-treatment platelet
as a P2Y12 reaction unit value 235 and/or a % inhibition 15%, as measuredpoinf Prim
holeste
n Colleg
ctivity wthe P
t Rea
nt; gro
norm
RP lev
efined
/l.
i
q
d
o
t
p
2638 Park et al. JACC Vol. 58, No. 25, 2011
Platelet Function Test and CRP After PCI December 13/20, 2011:2630–9confirm whether alteration of antiplatelet therapy based on
platelet function assay actually improves outcomes and to
propose how these measurements may be used in the future
care of patients.
In agreement with previous findings (7,8,20), the current
study also demonstrated that elevated CRP was significantly
associated with increased risks of major cardiovascular
events in patients receiving DES. The biological plausibility
in this group has been described elsewhere (8). In clinical
practice, there may be substantial interest in the use of a
readily available and simple marker, such as point-of-care
platelet function tests or serum biomarkers, to identify
high-risk patients for future cardiovascular events who could
be targeted for preventive measures. Our study suggests that
elevated CRP levels could more accurately identify a high
risk for major cardiovascular events in patients receiving
DES. However, we did not observe the long-term prognos-
tic value of HTPR, as measured by the VerifyNow P2Y12
assay. Interestingly, on the basis of the observed differences
of outcomes according to platelet reactivity in patients with
elevated CRP levels, one might pose the hypothesis that
elevated CRP could indicate a higher-risk population who
may benefit from a selective platelet function test or tailor-
ing antiplatelet therapy. Similarly, in the CREDO (Clopi-
dogrel for the Reduction of Events During Observation)
trial, patients with elevated CRP had increased athero-
thrombotic events, and the clinical benefit of clopidogrel
seems greater in those with elevated CRP, but not lower
CRP (21). A similar proof of concept was also documented
in a large clinical trial with statin treatment (22).
In our study, the rates of the primary endpoint were lower
than expected and were lower than rates reported in other
studies (3–6,14), for reasons that remain unclear. This could be
explained in part by differences in clinical or lesion character-
istics, interventional practice, or race or ethnic group between
our population of patients and those enrolled in earlier
studies, as previously noted (8,23,24). By contrast, the rate
of HTPR in our population was higher than rates reported
in other studies (3,6,14,15), even though similar cutoff levels
for HTPR were used among studies. This may be related in
part to the significantly higher incidence of the Asian
population having specific alleles on CYP2C19 that are
associated with poor metabolization of clopidogrel, as com-
pared with the Western population (25,26). In addition,
there may be the possibility of inter-racial variability of
platelet reactivity as noted in another study (27). Further
studies may be needed to determine the complex relation-
ships of genetic polymorphisms, platelet function assays,
and outcomes in different ethnic populations.
Study limitations. First, our study evaluated nonrandom-
zed, observational data. Second, given the relatively infre-
uent occurrence of hard endpoints, our analysis was un-
erpowered to detect a clinically significant difference in the
utcomes, and nonsignificant findings with platelet function
est might have been significant with a larger cohort of
atients. Therefore, our findings should be confirmed orrefuted through larger clinical studies with long-term
follow-up. Third, we did not perform serial measurements
of the VerifyNow P2Y12 assay and CRP. Platelet reactivity
or inflammatory status might be variable over time. Also,
optimal platelet reactivity may vary in the early or late period
after PCI. Finally, since the prognostic value of other
various platelet function tests was not tested, the direct
application of our findings to other studies or testing may be
limited.
Conclusions
In our cohort of patients treated with DES, the VerifyNow
P2Y12 assay failed to predict the risk of cardiovascular
events. However, high CRP levels were significantly asso-
ciated with long-term outcomes, suggesting that CRP
measurement might be useful for risk stratification for these
patients.
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